Similar retroviral and lentiviral technology can be applied to autologous haematopoietic stem cells, exemplified by Strimvelis and Zynteglo, licenced treatments for adenosine deaminase‐severe combined immunodeficiency (ADA‐SCID) and β‐thalassaemia respectively. Here, ADA is linked to severe combined immunodeficiency.